Frontiers in Oncology (Dec 2024)

Conversion surgery for stage IV gastric cancer after third-line immunotherapy: a case report

  • Sevindzh F. Evdokimova,
  • Anna L. Kornietskaya,
  • Larisa V. Bolotina,
  • Iliya V. Kolobayev,
  • Alexander A. Fedenko,
  • Andrey D. Kaprin,
  • Andrey D. Kaprin

DOI
https://doi.org/10.3389/fonc.2024.1494669
Journal volume & issue
Vol. 14

Abstract

Read online

The 5-year overall survival rate for stage IV gastric cancer is lower than 10%, despite the development of systemic therapy. Conversion surgery has shown to improve survival outcomes in patients with durable clinical response on chemotherapy. We report a clinical case of a patient, who underwent conversion surgery after pembrolizumab in the third-line setting for stage IV gastric cancer. The patient did not have recurrence for 22 months after conversion surgery.

Keywords